This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ho, D D Articles by Sato, V L Search for Related Content PubMed PubMed Citation Articles by Ho, D D Articles by Sato, V L

Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

ABSTRACT

Serum neutralizing antibodies against the human immunodeficiency virus were frequently detected in infected individuals, and low or absent serum neutralizing titers correlated with poor prognosis. Multiple diverse human immunodeficiency virus isolates were found to exhibit similar susceptibility to neutralization by a panel of human seropositive sera, suggesting that neutralizing antibodies are largely directed against conserved viral domains. Furthermore, utilizing antisera raised against a library of synthetic env peptides, four regions which are important in the neutralization process have been identified within both human immunodeficiency virus envelope glycoproteins (gp41 and gp120). Three of these are in conserved domains and should be considered for inclusion in a candidate vaccine.

This article has been cited by other articles:

• Heap, C. J., Reading, S. A., Dimmock, N. J. (2005). An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion. J. Gen. Virol. 86: 1499-1507 [Abstract] [Full Text]  
• Cheung, L., McLain, L., Hollier, M. J., Reading, S. A., Dimmock, N. J. (2005). Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion. J. Gen. Virol. 86: 131-138 [Abstract] [Full Text]  
• Trujillo, J. D., Kumpula-McWhirter, N. M., Hotzel, K. J., Gonzalez, M., Cheevers, W. P. (2004). Glycosylation of Immunodominant Linear Epitopes in the Carboxy-Terminal Region of the Caprine Arthritis-Encephalitis Virus Surface Envelope Enhances Vaccine-Induced Type-Specific and Cross-Reactive Neutralizing Antibody Responses. J. Virol. 78: 9190-9202 [Abstract] [Full Text]  
• Klasse, P. J., Sattentau, Q. J. (2002). Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83: 2091-2108 [Abstract] [Full Text]  
• Mascola, J. R., Louder, M. K., Winter, C., Prabhakara, R., De Rosa, S. C., Douek, D. C., Hill, B. J., Gabuzda, D., Roederer, M. (2002). Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells. J. Virol. 76: 4810-4821 [Abstract] [Full Text]  
• Srivastava, I. K., Stamatatos, L., Legg, H., Kan, E., Fong, A., Coates, S. R., Leung, L., Wininger, M., Donnelly, J. J., Ulmer, J. B., Barnett, S. W. (2002). Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus. J. Virol. 76: 2835-2847 [Abstract] [Full Text]  
• Stamatos, N. M., Mascola, J. R., Kalyanaraman, V. S., Louder, M. K., Frampton, L. M., Birx, D. L., VanCott, T. C. (1998). Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140. J. Virol. 72: 9656-9667 [Abstract] [Full Text]  
• Willett, B. J., Adema, K., Heveker, N., Brelot, A., Picard, L., Alizon, M., Turner, J. D., Hoxie, J. A., Peiper, S., Neil, J. C., Hosie, M. J. (1998). The Second Extracellular Loop of CXCR4 Determines Its Function as a Receptor for Feline Immunodeficiency Virus. J. Virol. 72: 6475-6481 [Abstract] [Full Text]  
• Haynes, B. (1993). Scientific and social issues of human immunodeficiency virus vaccine development. Science 260: 1279-1286 [Abstract]  
• Steimer, K., Scandella, C., Skiles, P., Haigwood, N. (1991). Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 254: 105-108 [Abstract]  
• Javaherian, K, Langlois, A., LaRosa, G., Profy, A., Bolognesi, D., Herlihy, W., Putney, S., Matthews, T. (1990). Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250: 1590-1593 [Abstract]  
• Homsy, J, Meyer, M, Tateno, M, Clarkson, S, Levy, J. (1989). The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244: 1357-1360 [Abstract]  
• Koff, W., Hoth, D. (1988). Development and testing of AIDS vaccines. Science 241: 426-432 [Abstract]  
• Walker, B., Flexner, C, Paradis, T., Fuller, T., Hirsch, M., Schooley, R., Moss, B (1988). HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240: 64-66 [Abstract]  
• Ho, D., Kaplan, J., Rackauskas, I., Gurney, M. (1988). Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239: 1021-1023 [Abstract]